Delta-9-Tetrahydrocannabinol
Huntington's Disease
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
25 Active assets in the Huntington's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deutetrabenazine Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | BBB |
Tetrabenazine William Ondo, MD | Phase 4 | BBB |
ro7234292 Hoffmann-La Roche | Phase 3 | BBB |
Dimebon Medivation, Inc. | Phase 3 | BB |
Pridopidine Prilenia | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Delta-9-Tetrahydrocannabinol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →